Helius Medical Technologies Receives Two Medical Method Patents

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

April 17, 2017

Helius Medical Technologies, Inc. (TSX: HSM, HSM.S and HSM.WT.S and OTCQB: HSDT) (“Helius” or the “Company”) announced today that it has been issued two medical method patents (U.S. Patent Nos. 5,597,501 and 5,597,504) that together further protect the intellectual property rights for its core asset, the PoNS™ device therapeutic techniques.

Helius Medical Technologies advises these patents bolster the current family of PoNS patents protecting various forms of physical and cognitive therapy combinations with both skin and oral cavity stimulation using the PoNS device or any equivalent neurostimulation device.

Helius Medical Technologies has now been issued or has allowed 40 US and international patents covering the medical method, design and device features associated with the PoNS device therapy.

“Further strengthening our intellectual property with these two new medical method patents is a very meaningful development for the company. I would like to thank the team at Proskauer Rose LLP for their invaluable support and effort in helping us secure our sizable patent portfolio,” said company CEO, Philippe Deschamps.

About PoNS™ Therapy

The Portable Neuromodulation Stimulator (PoNS™) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS™ Therapy combines the use of the device with physical or cognitive therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury.




Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.